Tirzepatide Therapy in Austin TX
Tirzepatide (mounjaro) FDA-approved in March 2022 as an adjunct to diet and exercise to improve glycemic control adults with type-2 diabetes mellitus, Tirzepatide injections is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide (GLP-1) receptor agonist.
In comparative head-to-head trials, Tirzepatide surpassed Semaglutide’s HbA1c reduction by an additional 24%.
According to data from Phase III trial results in type-2 diabetic patients, Tirzepatide was non-inferior and was
superior to Semaglutide with respect to the mean change in HbA1c from baseline to 40 weeks.
Impact of Tirzepatide
As a GIP and glp-1 receptor agonist, Tirzepatide is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life.
Tirzepatide selectively binds to and activates the GIP and GLP-1 receptors, the targets for native GIP
and GLP-1. As therapeutic doses, it acts on the brain and suppresses appetite. Used in conjunction with a healthy diet and exercise, Tirzepatide helps patients adhere to a reduced-calorie diet, enhancing the weight loss process.
Injectable Tirzepatide can be administered with or without food. If you need to change the day of the week, endure the previous dose was given 3 or more days before.
Potential Side Effects
The most common side effects include nausea, diarrhea, vomiting, constipation, stomach pain, headache, fatigue, dizziness, bloating, gas, and heartburn. More serious effects may include:
Pancreatitis (inflammation of the pancreas)
Serious allergic reactions
Increased heart rate